Wedbush Reaffirms Outperform Rating for Kura Oncology (NASDAQ:KURA)

Wedbush restated their outperform rating on shares of Kura Oncology (NASDAQ:KURA) in a research note issued to investors on Monday,RTT News reports. The firm currently has a $37.00 price target on the stock.

Other equities research analysts also recently issued reports about the stock. Cantor Fitzgerald reissued an “overweight” rating on shares of Kura Oncology in a research report on Monday, September 9th. UBS Group initiated coverage on Kura Oncology in a research note on Thursday, October 24th. They issued a “buy” rating and a $27.00 price target on the stock. StockNews.com downgraded Kura Oncology from a “hold” rating to a “sell” rating in a report on Thursday, August 22nd. HC Wainwright reissued a “buy” rating and set a $32.00 target price on shares of Kura Oncology in a research report on Thursday, October 24th. Finally, Stifel Nicolaus downgraded Kura Oncology from a “buy” rating to a “hold” rating and lowered their price target for the company from $26.00 to $19.00 in a report on Monday, October 14th. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating, six have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat.com, Kura Oncology currently has a consensus rating of “Moderate Buy” and a consensus price target of $28.83.

Kura Oncology Stock Down 0.4 %

Kura Oncology stock opened at $17.77 on Monday. The firm has a market capitalization of $1.36 billion, a P/E ratio of -7.97 and a beta of 0.86. The stock’s fifty day simple moving average is $18.85 and its 200-day simple moving average is $19.99. Kura Oncology has a twelve month low of $8.17 and a twelve month high of $24.17. The company has a current ratio of 14.94, a quick ratio of 14.94 and a debt-to-equity ratio of 0.02.

Kura Oncology (NASDAQ:KURA) last announced its quarterly earnings data on Thursday, August 8th. The company reported ($0.59) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.63) by $0.04. During the same period in the previous year, the firm posted ($0.53) earnings per share. The company’s revenue for the quarter was up .0% on a year-over-year basis. As a group, equities analysts expect that Kura Oncology will post -2.46 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Kura Oncology

A number of institutional investors and hedge funds have recently added to or reduced their stakes in KURA. Mirae Asset Global Investments Co. Ltd. raised its position in Kura Oncology by 12.8% in the 1st quarter. Mirae Asset Global Investments Co. Ltd. now owns 40,970 shares of the company’s stock valued at $874,000 after purchasing an additional 4,659 shares during the last quarter. SG Americas Securities LLC acquired a new stake in shares of Kura Oncology during the first quarter worth about $110,000. Susquehanna Fundamental Investments LLC purchased a new position in shares of Kura Oncology during the first quarter worth about $507,000. ProShare Advisors LLC increased its position in Kura Oncology by 9.7% in the 1st quarter. ProShare Advisors LLC now owns 18,014 shares of the company’s stock valued at $384,000 after acquiring an additional 1,588 shares during the period. Finally, Entropy Technologies LP purchased a new stake in Kura Oncology during the 1st quarter valued at approximately $218,000.

About Kura Oncology

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company’s pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.